Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial

Randall J. Bateman, Bruno Dubois, Alireza Atri et al.|The Lancet Neurology|2025

Cited by 39